171 related articles for article (PubMed ID: 16434086)
1. Systematic review of systemic therapy for advanced or recurrent endometrial cancer.
Carey MS; Gawlik C; Fung-Kee-Fung M; Chambers A; Oliver T;
Gynecol Oncol; 2006 Apr; 101(1):158-67. PubMed ID: 16434086
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.
Humber CE; Tierney JF; Symonds RP; Collingwood M; Kirwan J; Williams C; Green JA
Ann Oncol; 2007 Mar; 18(3):409-20. PubMed ID: 17150999
[TBL] [Abstract][Full Text] [Related]
3. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
Sorbe B; Andersson H; Boman K; Rosenberg P; Kalling M
Int J Gynecol Cancer; 2008; 18(4):803-8. PubMed ID: 17944917
[TBL] [Abstract][Full Text] [Related]
4. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
Long HJ; Nelimark RA; Podratz KC; Suman V; Keeney GL; Nikcevich DA; Kugler JW; Rowland KM; Kardinal CG; Wos EJ
Gynecol Oncol; 2006 Mar; 100(3):501-5. PubMed ID: 16185755
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
[TBL] [Abstract][Full Text] [Related]
6. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
[TBL] [Abstract][Full Text] [Related]
7. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy in endometrial cancer.
Obel JC; Friberg G; Fleming GF
Clin Adv Hematol Oncol; 2006 Jun; 4(6):459-68. PubMed ID: 16981669
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma.
Long HJ; Langdon RM; Cha SS; Veeder MH; Pfeifle DM; Krook JE; Ebbert LP; Tschetter LK; Roshon SG
Gynecol Oncol; 1995 Aug; 58(2):240-3. PubMed ID: 7622111
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.
Karagol H; Saip P; Uygun K; Kucucuk S; Aydiner A; Topuz E
Med Oncol; 2006; 23(4):543-8. PubMed ID: 17303913
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for metastatic and recurrent cervical cancer.
Scatchard K; Forrest JL; Flubacher M; Cornes P; Williams C
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006469. PubMed ID: 23076924
[TBL] [Abstract][Full Text] [Related]
14. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials.
Hogberg T
Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):463-9. PubMed ID: 18467080
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy in metastatic or recurrent endometrial carcinoma].
Deppe G; Baumann P; Munkarah A
Zentralbl Gynakol; 2000; 122(7):355-60. PubMed ID: 10951705
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA).
Moreira E; Paulino E; Ingles Garces ÁH; Fontes Dias MS; Saramago M; de Moraes Lino da Silva F; Thuler LCS; de Melo AC
Med Oncol; 2018 Jan; 35(3):20. PubMed ID: 29387971
[TBL] [Abstract][Full Text] [Related]
18. Treatment of recurrent and metastatic adenocarcinoma of the endometrium with cisplatin, doxorubicin, cyclophosphamide, and medroxyprogesterone acetate.
Fung MF; Krepart GV; Lotocki RJ; Heywood M
Obstet Gynecol; 1991 Dec; 78(6):1033-8. PubMed ID: 1945203
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
van Wijk FH; Aapro MS; Bolis G; Chevallier B; van der Burg ME; Poveda A; de Oliveira CF; Tumolo S; Scotto di Palumbo V; Piccart M; Franchi M; Zanaboni F; Lacave AJ; Fontanelli R; Favalli G; Zola P; Guastalla JP; Rosso R; Marth C; Nooij M; Presti M; Scarabelli C; Splinter TA; Ploch E; Beex LV; ten Bokkel Huinink W; Forni M; Melpignano M; Blake P; Kerbrat P; Mendiola C; Cervantes A; Goupil A; Harper PG; Madronal C; Namer M; Scarfone G; Stoot JE; Teodorovic I; Coens C; Vergote I; Vermorken JB;
Ann Oncol; 2003 Mar; 14(3):441-8. PubMed ID: 12598351
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma.
Cornelison TL; Baker TR; Piver MS; Driscoll DL
Gynecol Oncol; 1995 Nov; 59(2):243-8. PubMed ID: 7590480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
